RxDoctor Payments Data

Ellyn Johnson, OD

Optometrist · Advance, NCNPI 1386694917

Payments from drug & device makers

$2,375in general payments, 2019–2025

Across 81 payments — averaging $29.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$506
  • Coopervision Inc.$314
  • Lumenis BE Inc$310
  • Sun Pharmaceutical Industries Inc.$301
  • Oyster Point Pharma, Inc.$194
  • Bausch & Lomb Americas Inc.$179
  • plus $570 from 12 others

What the payments were for

  • Food & beverage$2,35599%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,375 in reported general payments places this provider in the 70th percentile of 1,326 optometrist providers in North Carolina.

See all optometrist providers in North Carolina

Medicare billing

Part B allowed, 2024
$31,339
Medicare patients
162
Services billed
406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine27$38,722
XiidraLifitegrast20$23,398
MieboPerfluorohexyloctane/Pf20$14,764
VyzultaLatanoprostene Bunod33$14,667
CequaCyclosporine13$10,637
LumiganBimatoprost18$8,761
TyrvayaVarenicline Tartrate11$6,933
RocklatanNetarsudil Mesylat/Latanoprost16$5,246
Loteprednol Etabonate39$3,743
Latanoprost218$3,263
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat63$1,078
Bimatoprost11$1,061
Fluorometholone12$537

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$179$52,82973 claims
AbbVieRestasis, Lumigan$18$47,48345 claims
Sun Pharmaceutical Industries Inc.Cequa$301$10,63713 claims
Oyster Point Pharma, Inc.Tyrvaya$194$6,93311 claims
Aerie Pharmaceuticals, Inc.Rocklatan$16$5,24616 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$93$3,74339 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,326 optometrist providers in North Carolina.

Other optometrist in Advance

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →